Developments in AI for Cancer Care: March 2025 Roundup

📰 Researchers at UChicago Medicine used an AI predictive discovery tool to identify a potential drug target, called PRMT5, for adenoid cystic carcinoma (ACC), a rare cancer of the salivary glands with few treatment options. A PRMT5-inhibitor called PRT543 has shown strong in vitro anti-tumor activity in combination with lenvatinib, a multi-kinase inhibitor. Read more here.

📰 Researchers at Weill Cornell Medicine developed an AI model to better predict how patients with muscle-invasive bladder cancer will respond to chemotherapy. Read more here.

📰 Researchers at UCLA, in collaboration with Avenda Health, developed an AI tool called Unfold AI, which could help improve treatment outcomes for men with prostate cancer. The tool can accurately estimate prostate tumor volume, which then helps physicians determine who is most likely to benefit from partial gland cryoablation. Read more here.

🚀 Myriad Genetics, Inc. has entered into an exclusive licensing partnership with PATHOMIQ, Inc. for the latter’s AI-powered technology platform for prostate cancer, called PATHOMIQ_PRAD. This partnership enables Myriad to provide urologists and radiation oncologists with AI tools that help guide clinical decision making across the prostate cancer care continuum. Read more here.

🚀 Clear Diagnostix recently introduced two AI-driven solutions to advance cancer care. KAI is an oncology-trained AI assistant that provides patients with real-time clarity on diagnoses, treatment plans, and medical terminologies, and provides healthcare organizations with AI-powered patient education and workflow support. The Second Opinion platform directly connects patients with vetted oncologists for timely insights. Read more here.

🚀 BullFrog AI, an AI-enabled drug discovery company is collaborating with Eleison Pharmaceuticals. By providing access to its BullFrog Data Networks™ AI solution, it can provide Eleison with safety, efficacy, and biomarker insights from its ongoing Phase 3 trial that can help optimize future clinical trial design. Read more here.

🚀 Johnson & Johnson MedTech announced FDA 510(k) regulatory clearance for MONARCH QUEST, a new software update that extends the capabilities of its MONARCH™ robotic lung biopsy system. The update allows for continuous vision for the physician and intra-procedural imaging, amongst other benefits, which could help improve accuracy in targeting lung nodules. Read more here.

🚀 Tempus AI has acquired Deep 6 AI, an AI-powered platform that helps healthcare and life science organizations “de-risk clinical trials, accelerate recruitment, and generate real-world evidence (RWE) with speed and precision”. Read more here.